Crystal forms of atorvastatin hemi-calcium and processes for...

Details Crystal forms of atorvastatin hemi-calcium and processes for... Crystal forms of atorvastatin hemi-calcium and processes for...

2005-10-24

2008-03-11

Powers, Fiona T (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

active

07342120

ABSTRACT:
The present invention provides novel forms of atorvastatin designated Forms VI, VIII, IX, X, XI and XII and novel processes for their preparation as well as processes for preparing atorvastatin Forms I, II, IV, V and amorphous atorvastatin.

REFERENCES:
patent: 4137322 (1979-01-01), Endo et al.
patent: 4681893 (1987-07-01), Roth
patent: 5003080 (1991-03-01), Butler et al.
patent: 5273995 (1993-12-01), Roth
patent: 5298627 (1994-03-01), Butler et al.
patent: 5686104 (1997-11-01), Mills et al.
patent: 5969156 (1999-10-01), Briggs et al.
patent: 6087511 (2000-07-01), Lin et al.
patent: 6121461 (2000-09-01), McKenzie
patent: 6476235 (2002-11-01), Butler et al.
patent: 6528661 (2003-03-01), Niddam et al.
patent: 6600051 (2003-07-01), Tully
patent: 6605636 (2003-08-01), Aronhime et al.
patent: 6605728 (2003-08-01), O'Connell et al.
patent: 6605729 (2003-08-01), Byrn et al.
patent: 2002/0099224 (2002-07-01), Niddam et al.
patent: 2002/0115709 (2002-08-01), Aronhime et al.
patent: 2003/0114686 (2003-06-01), Van der Schaaf et al.
patent: 2003/0212279 (2003-11-01), Tessler et al.
patent: 2003/0216584 (2003-11-01), Aronhime et al.
patent: 2004/0054193 (2004-03-01), Byrn et al.
patent: 2004/0077708 (2004-04-01), Grahek et al.
patent: 2004/0106670 (2004-06-01), Blatter et al.
patent: 2004/0220255 (2004-11-01), Van Der Schaaf
patent: 2004/0242899 (2004-12-01), Reddy et al.
patent: 2005/0209306 (2005-09-01), Jegorov et al.
patent: WO 97/03960 (1996-07-01), None
patent: WO 97/03958 (1997-02-01), None
patent: WO 97/03959 (1997-02-01), None
patent: WO 00/71116 (2000-11-01), None
patent: WO 02/057228 (2001-01-01), None
patent: WO 01/28999 (2001-04-01), None
patent: WO 01/36384 (2001-05-01), None
patent: WO 01/42209 (2001-06-01), None
patent: WO 01/44180 (2001-06-01), None
patent: WO 01/44181 (2001-06-01), None
patent: WO 02/41834 (2002-05-01), None
patent: WO 02/043732 (2002-06-01), None
patent: WO 02/051804 (2002-07-01), None
patent: WO 02/057229 (2002-07-01), None
patent: WO 02/059087 (2002-08-01), None
patent: WO 02/083637 (2002-10-01), None
patent: WO 02/083638 (2002-10-01), None
patent: WO 03/004470 (2003-01-01), None
patent: WO 03/011826 (2003-02-01), None
patent: WO 03/016317 (2003-02-01), None
patent: WO 03/018547 (2003-03-01), None
patent: WO 03/050085 (2003-06-01), None
patent: WO 03/070702 (2003-08-01), None
patent: WO 2004/022053 (2004-03-01), None
patent: WO 2004/050618 (2004-06-01), None
Declaration Under Rule 132 by Thomas M. A. Bocan, dated Dec. 2, 1998, filed in U.S. Appl. No. 08/945,812; 2 pages.
Declaration Under Rule 132 by Stephen R. Byrn, dated Nov. 25, 1998, filed in U.S. Appl. No. 08/945,812; 3 pages.
Rouchi, Chem. & Eng. News, Feb. 24, 2003, pp. 32-35.
Cheronis, Semimicro Experimental Organic Chemistry, pp. 31-49, 1958.
Haleblian & Crone, 1969, J. Pharm. Sci. 58:911-929.
David J. W. Grant, Theory and Origin of Polymorphism, in Drugs of the Pharmaceutical Sciences, vol. 95, Polymorphism in Pharmaceutical Solids, Chapter 1, (Harry G. Brittain ed., 1999).
G. Michael Wall, “Pharmaceutical Applications of Drug Crystal Studies”, Pharmaceutical Manufacturing (Feb. 1986) pp. 33-42.
U.S. Pharmacopia #23, p. 1843, 941 X-Ray Diffraction, 1995.
Pending U.S. Appl. No. 10/994,142, filed Nov. 19, 2004, Aronhime et al.
McCrone W.C., “Polymorphism”, Physics and Chemistry of the Organic Solid State, vol. 2, 1965, pp. 725-767.
Caira M.R., “Crystalline Polymorphism of Organic Compounds” Topics in Current Chemistry, Springer, Berlin, DE, vol. 198, 1998, pp. 163-208.
Graul A., et al., “Atorvastatin Calcium” Drugs of the Future, Barcelona, ES, vol. 22, No. 9, 1997, pp. 956-968.
Guillory, J.K.: “in Polymorphism in Pharmaceutical Solids (Brittain, H.G., ed.)”, 1999, Marcel Dekker, Inc., New York, Basel, pp. 183-226.
Hancock B.C., et al., “Characteristics and Significance of the Amorphous State in Pharmaceutical Systems”, Journal of Pharmaceutical Sciences, American Pharmaceutical Association, Washington, U.S., vol. 86, No. 1, Jan. 1997, pp. 1-12.
Concise Encyclopedia Chem. (1993), Walter deGruyter, Berlin, NY.
Thomas M.A. Bocan et al. “Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation”, Atheroselerosis 111 (1994) pp. 127-142.
Bang-Chi Chen et al., “Synthesis of Deuterium-Labeled Atorvastatin and its Metabolites for Use as Internal Standards in a LC/MS/MS Method Developed for Quantitation of the Drug and its Metabolites in Human Serum,” Journal of Labelled Compounds and Radiopharmaceuticals 43 (2000) pp. 261-270.
K.L. Baumann et al., “The Convergent Synthesis of CI-981, an Optically Active, Highly Potent, Tissue Selective Inhibitor of HMG-CoA Reductase,” Tetrahedron Letters, vol. 33, No. 17 (1992) pp. 2283-2284.
Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9thEd. (1996) pp. 879-881.

Affiliated with

Also associated with

Rating

Crystal forms of atorvastatin hemi-calcium and processes for... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Crystal forms of atorvastatin hemi-calcium and processes for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystal forms of atorvastatin hemi-calcium and processes for... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3960618